Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Advisory Committees
  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Radiology

abstract

  • IRC-determined results were highly consistent with those determined by investigators, demonstrating that bevacizumab plus GC provides a significant improvement in PFS and ORR. These results suggest that investigators can reliably assess disease progression and objective response in recurrent ovarian cancer using RECIST, without the necessity of a full IRC review.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2014.02.003

PubMed ID

  • 24508841

Additional Document Info

start page

  • 105

end page

  • 10

volume

  • 133

number

  • 1